EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Sotatercept: New drug on the horizon of pulmonary hypertension

Rosalinda Madonna, Filippo Biondi

Vascular Pharmacology · 2024-12 · 157 · 107442

DOI: 10.1016/j.vph.2024.107442 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vascular Pharmacology, 2024-12. Verfasst von Rosalinda Madonna und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical, Medical and Molecular Pathology and Critical Area, Cardiology Division, University of Pisa, Pisa, Italy. Electronic address: …. Hauptthemen laut MEDLINE: Activin Receptors, Type II, Pulmonary Artery, Antihypertensive Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: European Commission, Ministero dell’Istruzione, dell’Università e della Ricerca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sotatercept (brand name WINREVAIR, developed by Merck) is an activin receptor type IIA-Fc (ActRIIA-Fc), working by sequestering free activins. Sotatercept restores the balance between the activin proliferative pathway and the bone morphogenic protein (BMP) antiproliferative pathway in the pulmonary arterial cirulation. Sotatercept recently received approval in the USA and in Europe for the treatment of adults with pulmonary arterial hypertension (PAH) Group 1, on top of background PAH therapy to increase exercise capacity, improve WHO functional class and reduce the risk of clinical worsening events. Nevertheless, several studies are ongoing to investigate the potential adverse reactions of the drug especially at the haematological level. We provide an overview of the clinical and preclinical evidence of the targeting the activing pathway through sotatercept on the treatment of PAH. We also discuss what other possibilities there are for the application of sotatercept in the setting of pulmonary hypertension other than PAH Group 1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Activin Receptors, Type IIPulmonary ArteryAntihypertensive AgentsHumansAnimalsTreatment OutcomeRecombinant Fusion ProteinsSignal TransductionPulmonary Arterial HypertensionHypertension, PulmonaryArterial Pressure

Stichwörter der Autor:innen

ActivinBone morphogenic proteinPulmonary arterial hypertensionPulmonary remodelingSotatercept

Substanzen

Activin Receptors, Type IIAntihypertensive AgentsRecombinant Fusion ProteinsACVRL1 protein, human

Autor:innen und Institutionen

  • Department of Surgical, Medical and Molecular Pathology and Critical Area, Cardiology Division, University of Pisa, Pisa, Italy. Electronic address: rosalinda.madonna@unipi.it.
  • Department of Surgical, Medical and Molecular Pathology and Critical Area, Cardiology Division, University of Pisa, Pisa, Italy.

Förderung

  • European Commission
  • Ministero dell’Istruzione, dell’Università e della Ricerca

Zitieren

APA

Madonna, R., & Biondi, F. (2024). Sotatercept: New drug on the horizon of pulmonary hypertension. Vascular Pharmacology, 157, 107442. https://doi.org/10.1016/j.vph.2024.107442

Vancouver

Madonna R, Biondi F. Sotatercept: New drug on the horizon of pulmonary hypertension. Vascular Pharmacology. 2024;157:107442. doi:10.1016/j.vph.2024.107442

BibTeX
@article{Madonna2024,
  author = {Madonna, Rosalinda and Biondi, Filippo},
  title = {Sotatercept: New drug on the horizon of pulmonary hypertension},
  journal = {Vascular Pharmacology},
  year = {2024},
  volume = {157},
  pages = {107442},
  doi = {10.1016/j.vph.2024.107442}
}
Kostenlos starten →